AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02124798 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Belimumab autoinjector
Description: Single use, disposable autoinjector assembled with the prefilled syringe containing the drug product belimumab with unit dose strength of 200mg/mL and 1 mL will be given as a once weekly SC dose
Study NCT01845389 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Epidural (B. Braun)
Description: 20-gauge epidural catheter threaded cephalad through an 18 gauge needle identified by the loss of resistance method to air.
Study NCT01845389 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Spinal (Wiley Spinal Catheter)
Description: The Wiley Spinal® is an innovative Flexible Cannula over Needle designed for convenient intrathecal access. After dural puncture is achieved, an immediate dural seal is created. The flexible cannula is advanced off the needle ensuring cephalad delivery of medication.
Study NCT03907423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin10 mg tablet
Description: Diabetic patients treated with Rosuvastatin 10mg/day plus Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Study NCT03907423 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Diabetic patients treated with Glimepiride 1-8mg/day and Metformin 500-2550 mg/day oral
Study NCT05129202 — intervention group
Intervention type: DRUG
Intervention: immune therapy
Description: The patient receives immunotherapy
Study NCT00882765 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: genistein
Description: Given orally
Study NCT03520569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Octreotide
Description: we are using it to block insulin secretion from the pancreas
Study NCT00446212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propofol
Description: target controlled infusion of propofol
Study NCT00446212 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: desflurane
Description: Anaesthetic maintenance with desflurane
Study NCT03610412 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cinnamomum Cassia
Description: The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and the main effect sought is on IGF1 levels, in addition to metabolic control.
Study NCT03610412 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (calcined magnesia)
Description: The intervention period will be 90 days, unlike other trials with Cinnamomum cassia and comparison with placebo. The main effect sought is on IGF1 levels, in addition to metabolic control.
Study NCT03322657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Description: Neostigmine injection
Study NCT03322657 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycopyrrolate
Description: Glycopyrrolate injection
Study NCT03322657 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sugammadex
Description: Sugammadex injection
Study NCT00410371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Lamotrigine
Study NCT00410371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GI267119
Description: 25 mg ODT
Study NCT02189330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg of current commercial formulation.
Study NCT02189330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 12.2 mgA free acid tablet.
Study NCT02189330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 20 mg new soft gelatin capsule.
Study NCT02189330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 4 capsules of 20 mg tafamidis of current commercial formulation.
Study NCT02189330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tafamidis
Description: 4 capsules of 12.2 mg tafamidis of free acid tablet..
Study NCT02527304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Image-Guided Adaptive Radiation Therapy
Description: Undergo adaptive staged SBRT
Study NCT02527304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT02527304 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT02527304 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Stereotactic Body Radiation Therapy
Description: Undergo adaptive staged SBRT
Study NCT05890391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Time-Restricted Eating
Description: They were fed ad libitum between 10.00 a.m-06.00 p.m and fasted between 06.00 p.m-10.00 a.m.
Study NCT05890391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy-Restricted Diet
Description: The total energy expenditure (TEE) of individuals was determined using the 'Resting Energy Expenditure (REE) x Physical Activity Level (PAL) ' formulation. 'TEE-500 kcal' formulation was used for the diet to be given to individuals.
Study NCT03520569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin
Description: we are using to replace basal insulin and in two protocols to raise insulin concentrations during the insulin clamp
Study NCT03520569 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dextrose 20% solution
Description: We are using dextrose to maintain glycemia level
Study NCT03513146 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Oropharyngeal Administration of Mother's Milk (OPAMM)
Description: 0.2 ml of own mother's milk will be given by dropper to the oro-pharyngeal pouch, tongue and cheeks and the remaining amount will be given by the regular gavage feeding on intervals and amount regulated by the feeding protocol
Study NCT03202550 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone and Lorazepam (Active Comparator)
Description: Oxycodone and Lorazepam
Study NCT03202550 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: Placebo oral pills
Study NCT03425370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Closure of surgical wounds using buried sutures or tissue adhesive on aesthetic outcome.
Description: Effect of replacing buried sutures with tissue adhesive on aesthetic outcome of surgical wounds will be measured using the POSAS.
Study NCT00817102 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: FFR, IVUS, VH, or combination of the three
Description: Fractional Flow Reserve (FFR), Intravascular Ultrasound (IVUS), Virtual Histology (VH) or some combination of these three procedures will be completed during the cardiac catheterization procedure.
Study NCT02305459 — intervention group
Intervention type: DEVICE
Intervention: Yttrium-90 loaded SIR-Spheres microspheres
Description: Selective internal radiation therapy (SIRT), also called radioembolisation (RE), with SIR-Spheres microspheres is an endovascular procedure, included within the interventional oncologic technologies to treat primary and secondary liver tumours. Using a microcatheter, a precise dose of resin microspheres is released in the hepatic artery, where they are carried into the arterioles and selectively lodge in the tumour microvasculature. The microspheres are loaded with the radioactive yttrium-90, a high-energy beta-emitting isotope with a half-life of 64.1 hours. SIR-Spheres microspheres are manufactured by Sirtex Medical.
Study NCT02305459 — intervention group
Intervention type: BEHAVIORAL
Intervention: QLQ-C30 with HCC module
Description: In order to measure the palliative aspect of RE with SIR-Spheres microspheres, CIRT will incorporate a quality-of-life questionnaire. CIRT will be using EORTC's QLQ-C30 with HCC Module to measure changes in the quality of life of the patient. The quality-of-life questionnaire will be offered to the patient before the treatment, shortly after the treatment (as soon as possible) and at every follow-up. Filling out the quality-of-life questionnaire is entirely voluntary for the patient.
Study NCT02307500 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Regorafenib
Description: oral therapy
Study NCT02201082 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Airway clearance technique
Study NCT00969618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Description: 40-120 milligrams/day (mg/day) taken by mouth, once a day for 48 weeks
Study NCT00414440 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo comparator
Study NCT00414440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Everolimus
Description: experimental
Study NCT02201082 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amikacin nebulization
Study NCT02201082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amikacin nebulization
Study NCT01922661 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: REGN1908-1909
Study NCT01922661 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: placebo
Study NCT01037465 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: N-acetylcysteine
Description: N-acetylcysteine
Study NCT01037465 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04035083 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laser activated irrigation
Description: Diode laser at 980 nm, power of 1.5W, for 5 seconds inside the canal along with sodium hypochlorite, repeated 4 times with a gap of 10 seconds in between
Study NCT04035083 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Passive ultrasonic irrigation
Description: ultrasonic activation inside the canal for 1 min
Study NCT00086125 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ridaforolimus
Description: AP23573 12.5 mg IV as monotherapy once daily for 5 days, every 2 weeks
Study NCT00753142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intralipid 20%
Description: Participants receive a 48-hour infusion with Intralipid at 40 milliliters per hour (mL/hr).
Study NCT00753142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glucose infusion
Description: Participants receive a glucose infusion consisting of 10% dextrose infused intravenously at a rate of 200 mg/m\^2/min for 20 hours.
Study NCT03315689 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Vehicle Topical Solution
Study NCT03315689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-50002
Description: ATI-50002 Topical Solution
Study NCT02716142 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rectal misoprostol
Description: patients will take 2 tablets of rectally misoprostol 400 microgram 60 minutes before the procedure
Study NCT02716142 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sublingual misoprostol
Description: patients will take 2 tablets of sublingual misoprostol 400 microgram 60 minutes before the procedure
Study NCT01449994 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Activator IV (Activator Methods Int. Phoenix, Arizona)
Description: Instruments gives a defined impulse on specified areas of the body
Study NCT01449994 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Activator IV (Activator Methods Int. Phoenix, Arizona)
Description: Instruments gives a defined impulse on specified areas of the body
Study NCT04236466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: hyrax appliance
Description: Hyrax will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines.
Study NCT04236466 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: haas appliance
Description: Haas will be constructed with bands on maxillary first molars and wire extending on palatal surfaces of teeth till the upper canines. Acrylic part will be added on palate
Study NCT03744975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LCZ 696
Description: Participants will receive Oral LCZ 696 (Entresto 97/103 mg)
Study NCT03744975 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebos
Description: Participants will receive 1oral Placebo capsule
Study NCT03744975 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Participants will receive 1oral Placebo capsule
Study NCT06738810 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Fibrotest-actitest/NASHtest
Description: A blood sample will be collected from the patient in order to do Fibrotest-actitest/NASHtest and to calculate the NAFLD fibrosis score
Study NCT02839252 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Iggy and the Inhalers Asthma Education for Kids
Description: It is a comic book, trading cards, and stickers that teach kids about asthma. There is also a 12-minute cartoon video which teaches kids about asthma.
Study NCT02713750 — intervention group
Intervention type: OTHER
Intervention: reversible contraceptive methods
Description: 1. Consistent male condom use only~2. Consistent female condom use only~3. Hormonal contraception, combined oral contraceptive pills and male/female condom~4. Hormonal contraception, progestin only depot medroxyprogesterone acetate (DMPA) injectable and male/female condom~5. Hormonal contraception , progestin only hormonal implant and male/female condom~6. Intrauterine device and male/female condom
Study NCT04577651 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 16-contact Directional Deep Brain Stimulation
Description: Deep Brain Stimulation with 16-contact Directional Lead
Study NCT02968212 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clofazimine
Description: All participants in the experimental/treatment arm on this protocol will take a loading dose of 200 mg daily in soft capsule form of clofazimine for 16 weeks, dropping to 100 mg daily for the next 8 weeks.
Study NCT02968212 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: sugar pill
Description: All participants in the placebo arm on this protocol will take placebo in soft capsule form daily dropping to a smaller dose after 16 weeks to mirror the treatment arm dosing.
Study NCT04011644 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: A-CHESS self-monitored
Description: Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a research team member. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
Study NCT04011644 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A-CHESS peer-supported
Description: Patients have access to a smart phone app that provides information on tips on how to reduce drinking, a drink tracker, a journal, discussion boards, and private messaging with a counselor. Patients set weekly goals related to their drinking, reassess each week, and set a new goal for the upcoming week.
Study NCT01274377 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CMV Specific T Cell donor lymphocyte infusion
Description: Donor Lymphocyte Infusion (DLI)
Study NCT03154450 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EncoreAnywhere with data available to review
Description: Encore Anywhere will be installed and available for review by the clinical team
Study NCT01953276 — intervention group
Intervention type: DEVICE
Intervention: Serial Electrocardiograms
Description: All participants will have serial electrocardiograms performed.
Study NCT03154450 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: EncoreAnywhere with no data available to review
Description: Encore Anywhere will be installed but not available for review by the clinical team
Study NCT00472381 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Insulin
Description: Insulin
Study NCT04855812 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MyoMo
Description: To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
Study NCT04855812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Myo-SB
Description: To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
Study NCT04855812 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: To evaluate the usefulness of an upper extremity (UE) assistive device, called (MyoPro) in improving upper extremity activities in people with incomplete spinal cord injury (iSCI).
Study NCT02620111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Whey protein high in leucin
Description: This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein high in leucin
Study NCT02620111 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Whey protein normal in leucin
Description: This Group is analysed for muscle protein synthesis and breakdown, mTor pathway signaling and Amino acid metabolism while supplemented first water then whey protein normal in leucin.
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam hydrochloride
Description: Midazolam hydrochloride 2.5 mg
Study NCT02247830 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Chamomilla recutita gel
Description: Such intervention will be characterized by topical application of C. recutita gel, concomitantly to the initiation of radiotherapy, should be applied on the irradiated region three times daily throughout the period of realization of radiotherapy sessions area, and nursing consultations with equipment instructional (usual care).
Study NCT02247830 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Urea cream
Description: Experimental Group 02: usual care + Topical Application of Urea cream. The intervention will be characterized by topical application of urea-based cream on the irradiated region three times daily throughout the period of realization of radiotherapy sessions, in addition to nursing consultation with instructional material (usual care).
Study NCT02067221 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: RIRS
Description: * RIRS arm~* Use of flexible ureteroscopy to access and remove renal stones without percutaneous nephrostomy tract
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metoprolol tartrate
Description: Metoprolol tartrate 100 mg
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pioglitazone hydrochloride
Description: Pioglitazone hydrochloride 15 mg
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tolbutamide
Description: Tolbutamide 500 mg
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Omeprazole 20 mg
Study NCT03457597 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Relacorilant
Description: Relacorilant 350mg
Study NCT00743262 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Provox voice prosthesis
Description: The current voice prosthesis (Provox ActiValve)of the patients will be removed and a new prosthesis (Provox Vega) will be inserted
Study NCT02386579 — intervention group
Intervention type: PROCEDURE
Intervention: Blood sample measurements
Description: Blood samples are drawn in the feet and arms (a/v) before and after cooling the feet with ice water
Study NCT03261258 — intervention group
Intervention type: OTHER
Intervention: Questionnaire
Study NCT04874779 — intervention group
Intervention type: OTHER
Intervention: non
Description: follow up investigations
Study NCT02487706 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dolutegravir
Description: Dolutegravir 50mg/day per 5 days
Study NCT00623376 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nabilone then placebo
Description: The subjects were first on Nabilone, then crossed over to placebo
Study NCT00623376 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo then nabilone
Description: the subjects were first on placebo then crossed over to nabilone
Study NCT02067221 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MPCNL
Description: * MPCNL arm~* A new technique that reduced the size of percutaneous tract to make renal stone into small pieces.
Study NCT03084159 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Education worksheet
Description: Patients who screen positive for CKD and give written informed consent to be a part of the study will have their chart flagged for the medical assistant and provider to give the education worksheet intervention. The education worksheet has been developed to be used as an electronic tool within the Electronic Medical Record. The provider will review it with the patient during the visit. A paper copy will print out for the patient at the end of the visit.
Study NCT03886324 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: GIE Medical Drug Coated Balloon
Description: Stricture patients treated by DCB
Study NCT02477865 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEX168(100µg)
Description: 100µg,Subcutaneous injection,once a week. continued for 52 weeks